Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04636138 · ClinicalTrials.gov registry record · NA
Pharmacogenomic Modulators of Impaired Exercise Adaptation in Statin Users
A NA study of HMG-CoA Reductase Inhibitor Toxicity, sponsored by University of Kansas Medical Center.
- Active
- Registry status
- NA
- Development phase
- 5
- Enrollment target
- 1
- Study location
NCT04636138: Active NA study of HMG-CoA Reductase Inhibitor Toxicity, sponsored by University of Kansas Medical Center.
NCT04636138 is a NA study of HMG-CoA Reductase Inhibitor Toxicity that is active but no longer recruiting, run by University of Kansas Medical Center. The registered enrollment target is 5 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04636138, a NA study of HMG-CoA Reductase Inhibitor Toxicity, is active but no longer recruiting, sponsored by University of Kansas Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 5 participants
- Enrollment target
- 1
- Study location
Study Summary
3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) have beneficial effects (prevent stroke, heart attack) but also some bad ones (block some good effects of exercise). Individuals have genetic variations in proteins that metabolize/transport statins. The investigators hypothesize that these variations modulate the relationship between statin use and lack of benefit from exercise. The investigators will test this by having statin-users do supervised exercise for 6 weeks, measuring the cardiorespiratory fitness before/after and correlating this to genetic variations present in the participant.
Primary Outcome
Change pre/post intervention; compared with genomic variants
Conditions Studied
Interventions
- OTHER Exercise
Study Locations (1)
Kansas
- University of Kansas Medical Center - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2021-06-03 |
| Est. Completion | 2026-07-30 |
| Phase | NA |
What the registry record for NCT04636138 still lists
NCT04636138 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 1 condition, with HMG-CoA Reductase Inhibitor Toxicity appearing as the primary indexed condition, and to 1 intervention - of which Exercise is the first listed.
NCT04636138 reports a single indexed study location in Kansas.
Frequently Asked Questions
What is clinical trial NCT04636138 about?
NCT04636138 is a clinical study titled "Pharmacogenomic Modulators of Impaired Exercise Adaptation in Statin Users". 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) have beneficial effects (prevent stroke, heart attack) but also some bad ones (block some good effects of exercise). Individuals have genetic variations in proteins that metabolize/transport statins. The investigators hyp...
What is the current status of trial NCT04636138?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 5 participants. The study started on 2021-06-03. Estimated completion is 2026-07-30.
What conditions does trial NCT04636138 study?
This clinical trial studies the following conditions: HMG-CoA Reductase Inhibitor Toxicity.
What interventions are being tested in trial NCT04636138?
The interventions under investigation include: Exercise (OTHER).
Who is sponsoring clinical trial NCT04636138?
This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04636138 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04636138's enrollment target sits among peer trials
5 1988th of 2000 higher than 5 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI